KANE BIOTECH INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.13 CAD | +4.00% |
|
-7.14% | +62.50% |
| 18/04 | Transcript : Kane Biotech Inc. - Special Call | |
| 15/04 | Kane Biotech Up 12% After Reporting Closing of STEM Animal Health Sale | MT |
| Sales 2022 | 2.67M 1.95M 163M | Sales 2023 | 149K 109K 9.08M | Capitalization | 10.55M 7.7M 643M |
|---|---|---|---|---|---|
| Net income 2022 | -3M -2.19M -183M | Net income 2023 | -5M -3.65M -305M | EV / Sales 2022 | 6.37 x |
| Net Debt 2022 | 5.76M 4.21M 351M | Net Debt 2023 | 8.51M 6.21M 519M | EV / Sales 2023 | 128 x |
| P/E ratio 2022 |
-2.79
x | P/E ratio 2023 |
-2.02
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 65.07% |
More Fundamentals
* Assessed data
More news
Latest transcript on Kane Biotech Inc.
More press releases
| 1 day | +4.00% | ||
| 1 week | -7.14% | ||
| Current month | +30.00% | ||
| 1 month | +30.00% | ||
| 3 months | +52.94% | ||
| 6 months | +73.33% | ||
| Current year | +62.50% |
1 week
0.13
0.14
1 month
0.100.17
Current year
0.070.17
1 year
0.050.17
3 years
0.050.23
5 years
0.000.26
10 years
0.000.58
| Managers | Title | Age | Since |
|---|---|---|---|
Marc Edwards
CEO | Chief Executive Officer | - | 02/16/02 |
Ray Dupuis
DFI | Director of Finance/CFO | - | 05/17/05 |
| Compliance Officer | - | 12/19/12 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
R. Renaud
BRD | Director/Board Member | - | 15/10/15 |
| Chairman | 59 | 20/02 | |
Georges Morin
BRD | Director/Board Member | - | 20/20/20 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 29/24/29 | 0.13 | +4.00% | 26,200 |
| 26/24/26 | 0.125 | -3.85% | 31,500 |
| 25/24/25 | 0.13 | +4.00% | 12,000 |
| 24/24/24 | 0.125 | -3.85% | 150,900 |
| 23/24/23 | 0.13 | -7.14% | 27,500 |
Delayed Quote Toronto S.E., April 29, 2024 at 07:08 pm IST
More quotes
Kane Biotech Inc. is a Canada-based biotechnology company. The Company is engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms. It has a portfolio of biotechnologies and products, which includes StrixNB, DispersinB, Aledex, bluestem, bluestem, silkstem, goldstem, coactiv+, coactiv+, DermaKB and DermaKB Biofilm. Its Wound Care & Surgical division is focused on the product development of DispersinB for applications in chronic wound care. Its bluestem product line includes water additives, chews, spray and dental wipes. Its other products in development stage include Coactiv+, antimicrobial wound rinse for use in acute and chronic wounds; Coactiv+, antimicrobial surgical hydrogel for use in surgical and acute wounds, and DispersinB Gel for prosthetic joint infection. It also provides Scalp Detoxifier, Shampoo and Shampoo Bars. Its primary markets for its technologies are animal health and human health.
Calendar
22/05/2024
- Annual General Meeting
| 1st Jan change | Capi. | |
|---|---|---|
| +62.50% | 12.56M | |
| +1.77% | 42.86B | |
| +47.70% | 41.36B | |
| +12.24% | 42.74B | |
| -8.83% | 27.68B | |
| +7.44% | 25.15B | |
| -23.01% | 18.63B | |
| +30.56% | 12.37B | |
| -1.82% | 11.92B | |
| +8.35% | 11.21B |
- Stock Market
- Equities
- KNE Stock
